MAX
Company Analysis Propanc Biopharma, Inc.
1. Summary
Advantages
- Price (0.21 $) is less than fair price (3.14 $)
- Current debt level 8.8% is below 100% and has decreased over 5 years from 1616.16%.
Disadvantages
- Dividends (0%) are below the sector average (1.69%).
- The stock's return over the last year (-90.53%) is lower than the sector average (-7.71%).
- The company's current efficiency (ROE=-423.72%) is lower than the sector average (ROE=14.4%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Propanc Biopharma, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -9% | -22.6% | -0.8% |
| 90 days | -73% | -17.5% | 3.6% |
| 1 year | -90.5% | -7.7% | 12.3% |
PPCB vs Sector: Propanc Biopharma, Inc. has significantly underperformed the "Healthcare" sector by -82.82% over the past year.
PPCB vs Market: Propanc Biopharma, Inc. has significantly underperformed the market by -102.88% over the past year.
Slightly volatile price: PPCB is more volatile than the rest of the market on "OTC" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: PPCB with weekly volatility of -1.74% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.21 $) is lower than the fair price (3.14 $).
Price significantly below the fair price: The current price (0.21 $) is 1395.2% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.0144) is lower than that of the sector as a whole (41.11).
P/E vs Market: The company's P/E (-0.0144) is lower than that of the market as a whole (47.13).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.0608) is lower than that of the sector as a whole (3.58).
P/BV vs Market: The company's P/BV (0.0608) is lower than that of the market as a whole (4.27).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (3.9).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (12.15).
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.31) is lower than that of the sector as a whole (15.97).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.31) is lower than that of the market as a whole (24.87).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 569.23% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (569.23%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-45.01%).
6.4. ROE
ROE vs Sector: The company's ROE (-423.72%) is lower than that of the sector as a whole (14.4%).
ROE vs Market: The company's ROE (-423.72%) is lower than that of the market as a whole (50.34%).
6.6. ROA
ROA vs Sector: The company's ROA (-300.14%) is lower than that of the sector as a whole (7.44%).
ROA vs Market: The company's ROA (-300.14%) is lower than that of the market as a whole (35.3%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (14.06%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.86%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.69%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
